Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial - San-Miguel, Jesús F.; Weisel, Katja; Moreau, Philippe; Lacy, Martha; Song, Kevin; Delforge, Michel; Karlin, Lionel; Goldschmidt, Hartmut; Banos, Anne; Oriol, Albert; Alegre, Adrian; Chen, Christine; et al. (The lancet. Oncology, 2013)
Gesehen am 27.01.2022